HUMAN BILE SALT-STIMULATED LIPASE (BSSL) OBTAINABLE FROM TRANSGENIC SHEEP

Abstract: The present invention relates to human bile salt-stimulated lipase (BSSL) obtainable from transgenic sheep. The invention further relates to transgenic sheep whose germ cells and somatic cells contain a recombinant nucleotide molecule comprising a nucleotide sequence encoding for human BSSL. The invention also relates to methods for producing said transgenic animals, as well as to methods for producing human BSSL derived from transgenic animals. In addition, the invention provides the use of compositions comprising BSSL in the treatment of diseases relating to exocrine pancreatic insufficiency, and for improvement of the utilization of dietary lipids in preterm born infants.

Description: HUMAN BILE SALT-STIMULATED LIPASE (BSSL) OBTAINABLE FROM TRANSGENIC SHEEP TECHNICAL FIELD The present invention relates to human bile salt-stimulated lipase (BSSL) obtainable from transgenic sheep. The invention further relates to transgenic sheep whose germ cells and somatic cells contain a recombinant nucleotide molecule comprising a nucleotide sequence encoding for human BSSL. The invention also relates to methods for producing said transgenic animals, as well as to methods for producing human BSSL derived from transgenic animals. In addition, the invention provides the use of compositions comprising BSSL in the treatment of diseases relating to exocrine pancreatic insufficiency, and for improvement of the utilization of dietary lipids in preterm born infants. BACKGROUND ART Human Bile Salt-Stimulated Lipase Bile Salt-Stimulated Lipase (BSSL) is the major lipolytic activity present in human milk (Wang & Johnson, 1983; Wang & Hartsuck, 1993). As its name implies, the enzyme is not active in the milk but is activated in the intestine by bile salts. In mammals a similar enzyme activity is also secreted from the pancreas into the intestine. The cDNA sequences for both the mammary and pancreatic enzyme are identical indicating that they are the product of a single gene (Reue et al., 1991; Lidberg et al., 1992). BSSL shares with other pancreatic lipases a triacylglycerol hydrolase activity but BSSL is the only intestinal lipase which hydrolyses cholesterol ester and other fatty acid esters, such as vitamin A ester. The protein is stable to both proteases and the acid environment in infant stomachs. These unique activities and the large quantity of BSSL in human milk suggest that this enzyme is physiologically important. The cDNA sequence (SEQ ID NO: 2) and deduced amino acid sequence (SEQ ID NOS: 3 and 4) of BSSL have been disclosed by Nilsson et al. (1990); in US 5,200,183 (Oklahoma Medical Research Foundation); and in WO 91/18923 (Astra AB). Human BSSL is a glycoprotein consisting of 722 amino acids. The C- terminal portion is composed of 16 repeats each of 11 amino acids having the consensus PVPPTGDSGAP. The genomic DNA sequence (SEQ ID NO: 1) encoding human BSSL is disclosed by Lidberg et al. (1992) and in US 5,616,483 (Astra AB). BSSL is heavily glycosylated, with one potential N-linked glycosylation site (Asp 187) and two potential O-linked sites per repeat (Baba et al, 1991). Even though the glycosylation state of the enzyme is not critical for activity in vitro (Hansson et al, 1993), O-glycosylation nevertheless appears important for the biological function of BSSL. Loomes et al. (1997) have suggested that the C- terminal repeat region is important for prevention of non-specific hydrophobic interactions and that it counteracts a tendency of BSSL to self-aggregate. Wang et al. (1995) have shown that the repeat region contains different Lewis antigens, suggesting that it may also contribute to adhesive activity in the physiological function of BSSL. Spilburg et al. (1995) and Bosner et al. (1988) have suggested that the C-terminal domain may be important for heparin binding and interactions with proteoglycans on cell surfaces. Immunohistochemical experiments on mouse, rat and human tissues have indicated binding of the BSSL protein to intestinal cell membranes. O-glycosylation might thus be important for such binding of BSSL to a "BSSL-receptor" in the intestine and for proper physiological function of the enzyme. The expression of both cDNA and genomic constructs for BSSL, from the murine whey acidic protein (WAP) promoter, in the milk of transgenic mice have been disclosed (Strόmqvist et al, 1995). Levels of up to 1 mg/ml were obtained in milk and the protein was 100% active in vitro. However, the transgenic form of the enzyme exhibited a considerably reduced glycosylation state when compared to native enzyme or enzyme produced in cell culture. Recombinant human BSSL derived from transgenic mice apparently lacked the O-glycosylation pattern of native human enzyme. Expression of Heterologous Proteins in the Milk of Transgenic Animals The cloning and characterization of the ovine β-lactoglobulin (BLG) gene has been disclosed by Ali and Clark, 1988. It was demonstrated that BLG is consistently expressed at high levels in the milk of mice made transgenic for the entire gene (Simons et al, 1987; Harris et al, 1991). Further experiments demonstrated that the BLG promoter region can direct high levels of expression of a heterologous human protein to the milk of transgenic mice (Archibald et al, 1990). The generation of transgenic sheep, expressing human proteins in their milk using the BLG gene to drive expression, indicated that this technology might be viable as a commercial production route (Simons et al, 1988; Clark et al, 1989). The feasibility of applying this technology to the modification of livestock milks has been confirmed, demonstrating high level expression of human alpha- 1- antitrypsin in the milk of transgenic sheep (Wright et al, 1991; Carver et al, 1992; Carver et al, 1993; Cooper and Dalrymple, 1994). This high level expression of a heterologous protein in livestock milk was the result of using a fusion of the BLG promoter region to human genomic sequences (Wright et al, 1991). The vector pMAD6, disclosed in US 5,639,940, has been designed to express genes from the BLG promoter. BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1. Structure of plasmid pS452. Fig. 2. Schematic view of the construction of the clone pBSSLII. Fig. 3. Schematic view of the structure of pBSSLII. Fig. 4. BSSL activity in transgenic sheep. DISCLOSURE OF THE INVENTION It has surprisingly been shown that human bile salt-stimulated lipase (BSSL), produced in the mammary gland of transgenic sheep, has a distinct O- glycosylation pattern, which is in contrast to previous forms of BSSL produced in transgenic animals, and which may be important for the biological function of BSSL. The gene for human bile salt-stimulated lipase has been placed under the transcriptional control of the ovine β-lactoglobulin promoter and introduced into sheep. This resulted in the production of thirteen transgenic animals from 206 livebirths. Four transgenics were females. After inducing lactation in ewe lambs, expression of the transgene has been detected in the mammary gland and a range of levels of BSSL protein secreted into the milk. Expression levels in excess of 3 g 1 have been detected, a level which could form the basis of commercial production of human BSSL. The protein is fully active, carries glycosylation, and show the same enzyme characteristics as the native protein and the mammalian cell culture produced variants. Consequently, in a first aspect, the invention provides recombinant human bile salt-stimulated lipase (BSSL) produced by a transgenic non-human mammal, said lipase being glycosylated to at least 5%. The transgenic non-human mammal could be an ungulate placental mammal. In another aspect of the invention, the recombinant human BSSL is having a total monosaccharide content of above 10%. In yet another aspect, the recombinant human BSSL comprises at least 1 % N-acetylgalactosamine. In one embodiment of the invention, the recombinant human BSSL is characterised in comprising substantially the following monosaccharide composition: 0-6% fucose; 3-12% galactose; 0.1-2% mannose; 1-7% N- acetylgalactosamine; 0.5-15% N-acetylglucosamine; and 1.5-10% 5-Ac- neuraminic acid. In another aspect of this embodiment of the invention, the recombinant human BSSL is characterised in comprising substantially the following monosaccharide composition: 0-1% fucose; 6.5-8.5% galactose; 1-2% mannose; 5.5-7% N- acetylgalactosamine; 3.5-5% N-acetylglucosamine; and 2.5-4% 5-Ac-neuraminic acid. Preferably, the human BSSL comprises substantially the monosaccharide composition as shown in row 1 of Table IV. The recombinant bile salt-stimulated lipase according to the invention has substantially the amino acid sequence set forth as SEQ ID NO: 3 or SEQ ID NO: 4 in the Sequence Listing, or is comprising the amino acid sequence consisting functionally of SEQ ID NO: 3 or SEQ ID NO: 4 in the Sequence Listing. In another aspect, the invention provides a transgenic sheep whose germ cells and somatic cells contain a recombinant nucleotide molecule introduced into the said sheep, or an ancestor of said sheep, at an embryonic stage, said recombinant nucleotide molecule comprising (i) a nucleotide sequence encoding for human BSSL and (ii) a promoter operatively linked to the said nucleotide sequence encoding for human BSSL. In the transgenic sheep according to the invention, the nucleotide sequence encoding for human BSSL can be introduced as a genomic sequence including introns (SEQ ID NO: 1) or as cDNA (SEQ ID NO: 2). It has been reported that sequences comprising introns are preferable for regulated gene expression in transgenic animals (Brinster et al., 1988; Whitelaw et al., 1991). The plasmid pS452 (deposited under accession number DSM 7499) has a genomic fragment of BSSL (SEQ ID NO: 1) inserted into the first exon of the murine WAP gene. Consequently, the nucleotide sequence encoding for human BSSL may be of genomic or synthetic origin or any combination thereof. Specifically, the said nucleotide sequence can be selected from: (a) a nucleotide sequence carried by the plasmid pS452, identified by accession number DSM 7499; (b) a nucleotide sequence set forth as SEQ ID NO: lor SEQ LD NO: 2 in the Sequence Listing; (c) a nucleotide sequence encoding a polypeptide set forth as SEQ ID NO: 3 or SEQ LD NO: 4 in the Sequence Listing; (d) a nucleotide sequence which hybridizes with any of the sequences defined in (a), (b) or (c) under stringent hybridization conditions. The term "stringent hybridization conditions" is known in the art from standard protocols (e.g. Ausubel et al., supra) and could be understood as e.g. hybridization to filter-bound DNA in 0.5 M NaHPO 4 , 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at +65°C, and washing in O.lxSSC / 0.1% SDS at +68°C. It will be understood by the skilled person that for expression of the BSSL gene in the mammary gland of the transgenic sheep according to the invention, the nucleotide sequence coding for human BSSL should be linked to a gene encoding a milk protein, or a subsequence thereof, capable of mediating and targeting the expression of the BSSL gene to the mammary gland. In particular, there should be a promoter operatively linked to the said nucleotide sequence encoding for human bile salt-stimulated lipase. The said promoter can e.g. be the BSSL promoter, whey acidic protein promoter, or a milk protein promoter, such as a casein promoter, α-lactalbumin promoter or, preferably, a β-lactoglobulin promoter. The milk protein gene to be used may be derived from the same species as the one in which the expression system is to be inserted, or it may be derived from another species. It has been shown that the regulatory elements that target gene expression to the mammary gland are functional across species boundaries (Hennighausen et al., 1990). The mammary gland as a tissue of expression, as well as the use of genes encoding milk proteins, are generally considered to be particularly suitable for use in the production of heterologous proteins in transgenic non-human mammals, since milk proteins are naturally produced at high expression levels in the mammary gland. In addition, milk is readily collected and available in large quantities. In the present invention, the use of milk protein genes in the production of human BSSL has the further advantage that BSSL is produced under conditions similar to the natural production conditions in terms of regulation of expression and production location (the mammary gland). The signal peptide necessary for the secretion of BSSL into milk is shown as -23 to -1 in SEQ LD NO: 3. Consequently, a further aspect of the invention is a female transgenic sheep wherein the nucleotide sequence encoding for bile salt-stimulated lipase is expressed in the mammary gland of the said female transgenic sheep, and wherein bile salt-stimulated lipase is present in the milk of the said female transgenic sheep. Included in the invention is a process for production of a female transgenic sheep comprising: (a) providing a gene encoding for human bile salt-stimulated lipase operatively linked to a promoter functional in a sheep; (b) introducing said gene into an embryo or fertilized egg of a sheep, so as to incorporate said gene into the germline of the said sheep: (c) transplanting said embryo or fertilized egg into a pseudopregnant host sheep; (d) allowing said host sheep to produce progeny; (e) selecting a female progeny sheep that produces recoverable amounts of bile salt-stimulated lipase in its milk. The promoter mentioned in step (a) can e.g. be the BSSL promoter, whey acidic protein promoter, or or a milk protein promoter, such as a casein promoter, α- lactalbumin promoter or, preferably, a β-lactoglobulin promoter. Several methods can be used to introduce exogenous DNA into the developing mammalian embryo in such a way that it may ultimately become stably integrated into a chromosome of the resulting animal (e.g. Hogan et al., 1994; Umland et al., 1996). (a) The gene may be directly injected into a fertilized egg, e.g. a fertilized single cell egg or a pro-nucleus thereof, or an embryo of the sheep, by physically injecting it through a microscopically small-bore glass needle. The microinjected eggs may then subsequently be transferred into the oviducts of pseudopregnant foster mothers and allowed to develop. Normally, not all of the injected eggs will develop into adult females expressing human BSSL. Thus, about half of the mammals will from a statistically point of view be males from which, however, females can be bred in the following generations. Once integrated in the germ line, the gene encoding for human BSSL may be expressed at high levels to produce a correctly processed and functional human BSSL in stable lines of the mammal in question. Direct microinjection is labor intensive and technically demanding but would appear to have few limitations on the type or size of DNA that can be introduced. Within the last three years there have been several papers which describe the introduction of hundreds of kilobase pairs of contiguous DNA, in the form of yeast artificial chromosomes, into the mouse germ line (Schedl et al., 1993; Fujiwara et al., 1997; Manson et al., 1997). (b) Retroviruses can be genetically modified to act as vectors allowing the infection of embryos with exogenous DNA (Jaenisch et al., 1975; Gilboa et al., 1986). (c) Sperm has been claimed as an efficient mediator of exogenous gene transfer into mammalian embryos by one group (Lavitrano et al., 1989). (d) DNA recombination, homologous or non-specific, in embryonic stem cells can also be used to permanently modify the germline. Stem cells are pluripotent or totipotent cells derived from a mammalian embryo that are able to be grown in culture and which can contribute to a developing embryo (Evans & Kaufman, 1981; Robertson, 1987). The resulting animal possesses a number of cells derived from the embryonic stem cells, some of which may populate the germline and result in transmission of genetic material to the offspring (Robertson, 1987). Embryonic stem cells can also be genetically manipulated whilst in culture. DNA can be introduced into the cells using a variety of techniques (e.g. electroporation, lipofection, microinjection, retroviral infection and calcium phosphate precipitation). By employing the antibiotic G418, or exploiting the biochemistry of the enzyme thymidine kinase, transformed cells, that have incorporated exogenous DNA in a specific or non-specific way, can be positively and negatively selected (Bradley, 1991; Hooper, 1992). Very subtle alterations of the genome are possible, such as point mutations, as well as the generation of specific deletions (so-called "knock outs", e.g. Stacey et al., 1994) or replacements (Stacey et al., 1994; Stacey et al., 1995). However, to date this method has only been successful in the mouse. Embryonic stem cells have only demonstrably been isolated from murine embryos, the search in other species continues (McWhir et al., 1996). (e) In vitro manipulation of somatic or other cells (e.g. using homologous recombination as above) followed by the generation of an animal by nuclear transfer. Wilmut and co-workers (Wilmut et al., 1997) described the successful cloning of a sheep by nuclear transfer from both foetal and adult cells. The adult cell in question was derived from a line which had been grown in vitro for many passages. This new technology takes an enucleated, unfertilized, egg and places another cell into the space between the zona pellucida and the cytoplasmic membrane. The membranes of the two cells are fused with an electric pulse. Reconstructed embryos are allowed a brief development period in a temporary sheep recipient before final evaluation and introduction into a synchronized ewe. 10 Thus, it is conceivable that adult or foetal livestock cells can be manipulated in vitro, with much the same technology as is used for the alteration of murine embryonic stem cells, and then used to generate transgenic animals. Indeed, there are now transgenic sheep which have been made by such an approach, whereby a human gene under the control of BLG has been introduced into cells in vitro, prior to nuclear transfer (Schnieke et al., 1997). In a further aspect, the invention provides a process for production of human bile salt-stimulated lipase comprising: (a) producing milk in a female transgenic sheep as defined above; (b) collecting the milk produced in step (a); and, optionally, (c) isolating the bile salt-stimulated lipase. More specifically, the said process for production of human bile salt-stimulated lipase can comprise: (a) providing a gene encoding for human bile salt-stimulated lipase operatively linked to a promoter functional in a sheep; (b) introducing said gene into an embryo or fertilized egg of a sheep, so as to incorporate said gene into the germline of the said sheep: (c) transplanting said embryo or fertilized egg into a pseudopregnant host sheep; (d) allowing said host sheep to produce progeny; (e) selecting a female progeny sheep that produces recoverable amounts of bile salt-stimulated lipase in its milk; (f) collecting the milk produced by the female sheep selected in step (e); and, optionally, (g) isolating the bile salt-stimulated lipase. The promoter mentioned in step (a) can e.g. be the BSSL promoter, whey acidic protein promoter, or a milk protein promoter, such as a casein promoter, α- lactalbumin promoter or, preferably, a β-lactoglobulin promoter. 11 In the above mentioned processes for production of a female transgenic sheep, or for production of human BSSL, the said gene encoding for bile salt-stimulated lipase can preferably have a nucleotide sequence selected from (a) a nucleotide sequence carried by the plasmid pS452, identified by accession number DSM 7499; (b) a nucleotide sequence set forth as SEQ ID NO: 1 or SEQ ID NO: 2 in the Sequence Listing; (c) a nucleotide sequence encoding for a polypeptide set forth as SEQ LD NO: 3 or SEQ ID NO: 4 in the Sequence Listing; (d) a nucleotide sequence which hybridizes with any of the sequences defined in (a), (b) or (c) under stringent hybridization conditions. The invention includes recombinant human BSSL obtainable by the above mentioned processes for producing human BSSL. recombinant human bile salt- stimulated lipase (BSSL) produced by a transgenic non-human mammal, said lipase being glycosylated to at least 5%. The said recombinant human BSSL may have a total monosaccharide content of above 10%, and/or may comprise at least 1% N-acetylgalactosamine. The said recombinant human BSSL is characterised in comprising substantially the following monosaccharide composition: 0-6% fucose; 3-12% galactose; 0.1-2% mannose; 1-7% N-acetylgalactosamine; 0.5- 15% N-acetylglucosamine; and 1.5-10% 5-Ac-neuraminic acid. In another aspect the recombinant human BSSL is characterised in comprising substantially the following monosaccharide composition: : 0-1% fucose; 6.5-8.5% galactose; 1- 2% mannose; 5.5-7% N-acetylgalactosamine; 3.5-5% N-acetylglucosamine; and 2.5-4% 5-Ac-neuraminic acid. More preferably, the said human BSSL comprises substantially the following monosaccharide composition: 0-1% fucose; 6.5-8.5% galactose; 1-2% mannose; 5.5-7% N-acetylgalactosamine; 3.5-5% N- acetylglucosamine; and 2.5-4% 5-Ac-neuraminic acid. Most preferably, the human BSSL comprises substantially the monosaccharide composition as shown in row 1 of Table IV. Preferably, the recombinant bile salt-stimulated lipase according to the invention has substantially the amino acid sequence set forth as SEQ LD NO: 3 or SEQ ID NO: 4 in the Sequence Listing. 12 In another aspect, the present invention provides a pharmaceutical preparation comprising human BSSL derived from the transgenic as described above. The preparation may be prepared by adding the recombinant human BSSL in a purified or partly purified form to the normal constituents of a pharmaceutical preparation, such as a pharmaceutically acceptable carrier. In yet another aspect, the invention provides the use of the bile salt-stimulated lipase described above in the manufacture of a medicament for the treatment of a pathological condition related to exocrine pancreatic insufficiency, e.g. in cystic fibrosis. Included in the invention is also the use of bile salt-stimulated lipase as described above in the manufacture of a medicament for the improvement of the utilization of dietary lipids in preterm born infants. The invention also provides a method for treatment of a pathological condition related to exocrine pancreatic insufficiency, e.g. in cystic fibrosis, which comprises administering to a mammal, including man, in need of such treatment an effective amount of bile salt-stimulated lipase as described above. The term "effective amount" should in this context be understood as that amount required to restore fat digestion and repair the physiological deficit. Included in the invention is also a method for the improvement of the utilization of dietary lipids in preterm born infants which comprises administering to a preterm born infant in need of such improvement an effective amount of bile-salt stimulated lipase as described above. Throughout this description the terms "standard protocols" and "standard procedures", when used in the context of molecular cloning techniques, are to be understood as protocols and procedures found in an ordinary laboratory manual such as: Current Protocols in Molecular Biology, editors F. Ausubel et al., John Wiley and Sons, Inc. 1994, or Sambrook, J., Fritsch, E.F. and Maniatis, T, Molecular Cloning: A laboratory manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1989. 13 EXAMPLES 1. PREPARATION OF GENETIC MATERIAL The plasmid pS452 (deposited under the Budapest Treaty with accession number DSM 7499) was used. This construct has a genomic fragment of BSSL (SEQ ID NO: 1) inserted into the first exon of the murine WAP gene (Stromqvist et al., 1996). The features of pS452 is further shown in Fig. 1 and Table I. The plasmid DNA was introduced into the E.coli strain DH5α by standard transformation methods. Twelve clones were screened for the presence of pS452 and all contained the plasmid. DNA from clones 5-8 was pooled and renamed pBSSLI. This miniprep DNA was used for subsequent manipulations. 1.1 Subcloning of BSSL sequences into pMADό pBSSLI was restricted with Kpnl and Sail in order to excise the BSSL genomic sequences. The DNA was phenol extracted, ethanol precipitated and resuspended in water. The digest was treated with T4 DNA polymerase to produce blunt ends. The DNA was size fractionated on a 0.5% agarose gel and the band corresponding to BSSL excised and purified using the Prepagene system (Biorad). Purified BSSL fragment was ligated into the EcoRV site of the BLG vector pMAD6 (see Fig. 2) and transformed into E. coli DH5a by standard techniques. Bacterial colonies were screened by a standard alkaline lysis miniprep method. Colonies were initially screened with H dHI to visualize BSSL insertion and orientation. 1.2 Preparation of plasmid DNA The correct orientation and integrity of clones corresponding to a BLG/BSSL hybrid were confirmed by restriction digest with the enzymes BamHl, HinάΩl, 14 Mlul, Ncol, Sphl, Stul andXbal. One clone was chosen and named pBSSLII. DNA from pBSSL II was prepared by standard alkaline lysis followed by CsCl gradient ultracentrifugation. 1.3 Confirmation of the structure of pBSSLII The new junction sequences were confirmed initially by double stranded DNA sequencing using primers reading across the EcoRW site in pMAD6. Subsequently, the entire exon coding parts of pBSSLII were completely sequenced in order to confirm its structure. Sequences were obtained using an ABI377 automatic sequencing machine and associated double strand sequencing technologies. The sequence data was compiled into its final form using the Autoassembler™ (ABI) program and aligned against the expected DNA sequence. There were no changes from the expected DNA sequence. In order to confirm that all of the repeat structure of BSSL was present in the plasmid, this region was sequenced from both sides. It was confirmed that all 16 of the 33 base pair repeats (corresponding to the 11 amino acid repeat) were present in the construct. 1.4 Preparation of DNA for injection The BSSL II transgene was excised from its bacterial vector backbone by restriction with Mlul. DNA for microinjection was separated from vector backbone by rate zonal ultracentrifugation in 20 - 40% linear sucrose gradients. Fractions from the gradients were analyzed by agarose gel electrophoresis and vector free insert fractions pooled. DNA was ethanol precipitated and resuspended in water. Pooled BSSL II DNA was subjected to a second round of sucrose density gradient ultracentrifugation in order to minimize bacterial vector contamination. The concentration of the final product was determined by ultraviolet spectrophotometry using the GeneQuant II instrument (Pharmacia) and the DNA checked by agarose gel electrophoresis. 15 2. PRODUCTION OFTRANSGENIC SHEEP 2.1 Source and organization of the animals The study used only adult ewes and adult rams of the Poll Dorset breed which had been resident at PPL Therapeutics, East Mains, Ormiston, since their importation from New Zealand or which were born at East Mains. All ewes were more than 12 months old at the start of the study. All rams had proven fertility during 1994. Ewes and ewe hoggs of the Poll Dorset breed or Poll Dorset cross breed which had been resident at PPL Therapeutics, East Mains, Ormiston since their importation from New Zealand or which were born at East Mains or Poll Dorset ewes and ewe hoggs imported from New Zealand. The study was divided up first by week ( 1-5) and then further subdivided into four injection groups. Each group had 7 donors and 25 recipients. 2.2 Methods 2.2.1 Donors All ewes were treated with an intravaginal progesterone impregnated sponge (Chronogest Goat Sponge - Intervet) on the start date, day -13, -14, -15 or -16. These were left in situ for 12 to 15 days and removed on day -1. Donors were treated with a total of 1.0 units of ovine follicle stimulating hormone (OFSH) (Ovagen, Immuno-Chemical Products Ltd), given over four days, starting on day -4 and finishing on day 0. Donors were also treated with 400 IU of a follicle stimulating hormone substitute (PMSG-Intervet) on day -3 to provide additional follicle stimulating and luteolysing activity. 16 Donors were injected intramuscularly with 2 ml of a synthetic releasing hormone analogue (Receptal-Hoescht Animal Health) on day 0. Donors were fertilized by intrauterine artificial insemination (Al). All rams used for Al were semen assessed prior to the start of the study. Donors were starved of food and water for at least 12 hours before Al and artificially inseminated by intrauterine laparoscopy under general anaesthesia (GA) on day 1. GA was induced by an intravenous injection of 5% thiopentone sodium (Intraval Sodium, RMB Animal Health Ltd) and maintained by inhalation of 1-2% Halothane/O 2 /N 2 O after intubation. Al was carried out using freshly collected semen from a Poll Dorset ram. Semen was diluted with equal parts of sterile phosphate buffered saline or Ultra Heat Treated Milk (Anchor Standard Milk from New Zealand) and 0.2 ml of the diluted semen injected per uterine horn. Embryos were recovered from donors on day 2. Donors were starved of food and water from day 1. Embryo recovery was carried out by GA (as in 2.2.1.5). Donors were allowed to recover after an intramuscular injection of Temgesic (Reckitt and Colman) and an intramuscular injection of Amoxypen LA (Mycofarm UK Ltd) at the manufacturers recommended dose rate before transfer to the surgery. A laparotomy incision was made and the uterus exteriorized. Embryos were recovered by retrograde flushing of the oviducts with Ovum Culture Medium (Immuno-Chemical Products Ltd). After flushing, the uterus was returned to the abdomen and the incision closed. 2.2.2 Embryo microinjection All one cell embryos with visible pronuclei were microinjected into one pronucleus with approximately 2 pi of DNA from a solution at 6 μg/ml in TE (10 mM Tris, pH 7.5/ 0.1 mM EDTA). The DNA was prepared and diluted to approximately 6 μg/ml, stored frozen at 17 -20°C in 40 μl aliquots. A photographic record of the quality of the DNA preparation used was made, prior to aliquoting and subsequent microinjection. On each microinjection day an aliquot of the DNA was removed from the freezer and allowed to thaw at room temperature. The aliquot was labelled with the group number and used for microinjection on that day only. Any DNA remaining after microinjection was refrozen at -20°C and stored for subsequent analysis. At the end of each week these frozen aliquots of "used" DNA were analyzed by electrophoresis and photographed. 2.2.3 Recipients (a) Sponging All recipients had an intravaginal progesterone impregnated sponge (Chronogest Ewe Sponge - Intervet) inserted on the start date, day -13, -14, -15 or -16. These were left in situ for 12-15 days and removed on day -1. Recipients received 2.0 ml (400 IU) of a follicle stimulating hormone substitute (PMSG - Intervet) intramuscularly at sponge removal on day -1. If the sponge was missing the ewe received 0.5 ml Estrumate and not PMSG. Recipients were tested for oestrus with a raddled vasectomized ram between 0800 and 1700 hours on days 0 and 1. The vasectomized ram may run permanently or intermittently with the ewes throughout this period. Ewes were checked at least twice daily for onset of oestrus. (b) Recipient transfer Embryos surviving microinjection were returned to recipients on day 2. Recipients were starved from day 1. Embryo return was carried out under general anaesthesia and analgesia (as in 2.2.1.5). The uterus was exteriorized via a 18 laparotomy incision. Embryos were returned to one or both oviducts only in ewes with at least one suitable corpora lutea. After replacement of the uterus the abdomen was closed and the recipients allowed to recover. All transferred recipients were ultrasonically scanned for pregnancy and number of foetuses carried between the 50th and 90th days of pregnancy, Day 50 - 90. The pregnant recipients were vaccinated against erysipelas, using Erysorb ST (Hoechst Animal Health) and against clostridial disease and pasteurellosis using Heptavac P (Hoechst Animal Health). They either received a single booster dose of each vaccine or a primary course of two injections depending on their previous vaccination history. All vaccinations were carried out according to manufacturer's instructions. (c) Lambing If the ewe had not already lambed, lambing was induced at 1400 hours on Day 145 of pregnancy by an intramuscular injection of 8 ml Soludex (Mycofarm). Twenty-four hour supervision of lambing was provided. Recipient ewes were placed in an individual pen with their lambs as soon as possible after lambing, and remained individually penned for at least 24 hours post-lambing. The afterbirths were removed from the individual pens as soon as possible after their expulsion by the ewe. All lambs were identified by an ear tag bearing their individual number in each ear and by a transponder in the left groin. Lambs were ear tagged before they left the individual pens. All lambs were left with their dams for rearing. Ewes and lambs may remain housed and fed complete diet, concentrates, other supplements and/or ad lib straw 19 or may go out to grass. If necessary, the lambs were treated with an appropriate insecticidal pour-on product before being turned out to grass. (d) Lambs - tail sampling All lambs had a sample of tail tissue taken within the first week of life, unless this would prejudice their health, in which case sampling, was delayed until the lamb was considered well enough. A burdizzo (The Ritchey Nipper, Ritchey Tagg Ltd) was applied to the tail below, but as close as possible to, the ring. The jaws of the burdizzo were closed and held firmly shut. The jaws were then opened and the burdizzo removed. Using a pair of scissors or scalpel blade the tail was removed at the level of the crush mark left by the burdizzo. As soon as the tail was removed the tip was shaved up and a 1 cm length cut off the tip. The 1 cm length tip was placed into a plastic bijou. Tail samples were analyzed as soon as possible after their collection for the presence of the transgene. Immediately after the removal of the tail the lamb was given an intramuscular injection of Duphapen LA (Solvay Duphar) at the manufacturers recommended dose rate and the cut end of the tail was treated with an antibiotic spray or powder. All lambs born dead or dying before tail sampling had samples of tail taken and frozen as soon as possible after death. Tail samples were also taken from lambs in utero of dead recipient ewes. The samples were frozen at -20°C or below as soon as possible after they have been taken. (e) Lambs - blood sampling All lambs had a blood sample taken from the jugular vein into an EDTA vacutainer at 14 days of age or older, unless this would prejudice their health, in which case sampling was delayed until the lamb was considered fit enough. 20 2.3 Induction of lactation and milking of GO females On days 1-7 Oestradiol Benzoate (5 mg/ml - Intervet) and Progesterone (25 mg/ml - Intervet) were injected subcutaneously. On days 18-20, Dexamethasone (Soludex Injection -Mycofarm) was injected intramuscularly once daily. The udder of each ewe lamb was examined for mammary development and milk secretion on Day 21. Lactation should begin on Day 21. If milk was produced, all of it was collected from each half of the udder by expressing the milk into 50 ml Falcon tubes. Milk from the 2 halves may be bulked together. The total volume collected at each milking was recorded. Milking was then continue twice daily. Milk (0.5 - 1.0 ml) from each milking was taken from the bulk milk sample and placed in a plastic bijou. All milk was placed in a -20°C freezeer until required for analysis. 3. ANALYSIS OF SHEEP SAMPLES FOR THE PRESENCE OF THE TRANSGENE Two tissues are routinely sampled and analyzed for the presence of the transgene, blood and tail. In general, the tail material is made available prior to blood and thus tail is analyzed first. The gap between delivery of the two samples is around one week and therefore tail and blood samples are never assayed in the same experiment. This provides some degree of safety and reduces the likelihood of discarding a positive animal as negative. 3.1 Processing lamb tail samples Roughly 10 mm 3 of sheep tail was placed into 1 ml Tail Buffer (0.3 M sodium acetate / 50 mM KC1 / 1.5 mM MgCl 2 / 10 mM Tris (pH 8.5) / 0.5% NP40 / 0.5% Tween-20) in a plastic bijou. Proteinase K (Boehringer Mannheim) was added to a 21 final concentration of 0.5 mg/ml and the samples incubated at +55°C, with vigorous shaking, overnight. Approximately 1 ml of digested tail material was extracted first with phenol and then CHC^/Isoamyl alcohol (24: 1) before isopropanol precipitation, ethanol wash and air drying. Precipitated DNA was resuspended in 50-200 μl of water. 3.2 Processing lamb blood samples The Nucleon™ Kit (Scotlab) was used to purify DNA from the white cells in whole blood, according to the manufacturer's instructions. Basically, the method uses sodium perchlorate to solubilize protein and a silica matrix to capture the DNA. Approximately 1.5 ml of whole blood was extracted. The DNA was resuspended in 50 μl of TE (10 mM Tris, pH 8.0/1 mM EDTA). 3.3 Analysis of DNA by Southern blotting 15 μl of each sample was cut with the restriction enzyme Bamϋl, according to the manufacturers instructions. Restricted DNA samples were quantified using the GeneQuant II instrument (Pharmacia) and aliquots corresponding to 10 μg of material were electrophoresed on a 1% agarose gel. Fractionated DNA was transferred to a nylon membrane support (Duralon-UV, Stratagene) by capillary transfer and crosslinked to the support by UV light. Approximately 20 ng of a 1.8 kbp BamHUEcoRV fragment, encoding the first 1.8 kbp of the BLG promoter, was radiolabelled with [α- 32 P]dCTP using a random prime labelling kit (Boehringer Mannheim). Probe and membranes were hybridized in roller bottles, in a buffer 7% SDS/0.5 M NaPJl mM EDTA (pH 7.2), for 12-16 hours at +65°C. Excess probe was removed by stringent washes and signal determined by autoradiography. 22 4. ANALYSIS OF MILK SAMPLES FOR THE PRESENCE OF RECOMBINANT BSSL 1 μl and 0.1 μl of each sheep milk sample was introduced into 10 μl of 2 x reducing sample buffer and loaded on to No vex 4-12% linear gradient gels (SDS- PAGE). Control sheep milk and native BSSL were loaded in the same manner. Native BSSL, prepared according to Hansson et al. (1993) and Blackberg et al. (1995) acted as a standard and was loaded at a concentration of 0.2 mg/ml. Gels were run at 150 V and stained with Coomassie Brilliant Blue. Proteins were visualized after destaining. Approximate quantitation was achieved by comparison with known masses of native BSSL. 5. RESULTS FROM THE SHEEP STUDY 5.1 Embryology A summary of the lambing results is presented in Table II. 5.2 Screening A diagrammatic representation of the construct is shown in Fig. 3. The bar, labelled \ , represents the labelled probe, which is specific for the BLG promoter. This probe will anneal to the endogenous BLG gene and the transgene, if present. The size of the hybridizing transgene band is 6.4 kbp. B = BamR I. Animals determined to be transgenic from tail DNA, blood DNA or both were subjected to a second round of analysis with a single Southern blot containing both tissue samples. It was shown that the four females have a relatively low transgene copy number. Some of the males, in particular 60232 and 60364 had copy numbers which may be considerably greater than 10. All animals were positive in both tail and blood samples. 23 A summary of the transgenic data is shown in Table II, thirteen animals in total, four females and nine males. The levels of transgenesis seen in this study, as a function of live births, are comparable to the highest levels of transgenesis that have been obtained in sheep. There is no data to suggest that the skew towards male animals is anything other than chance. 6. MLLK ANALYSIS 6.1 Induced lactation Four ewe lambs, transgenic for hBSSL, were induced to lactate, their numbers and ages are outlined in Table III. In addition, a non-transgenic ewe lamb of similar age was induced as a negative control. All five lambs produced milk. The daily volumes were recorded. All lambs gave several hundred ml of induced milk (total volume between 190 to 2100 ml during 26 days of lactation). 6.2 Levels of human BSSL in milk Analysis of the expression of hBSSL in sheep milk shows that a 107 kDa protein, corresponding to the BSSL standard, was present in all four transgenic milks, but not the negative control. The levels of the protein in the milk of 60276 did not vary greatly across the period of the lactation. 7. BIOCHEMICAL CHARACTERIZATION 7.1 Proteins used Native BSSL from human milk as well as recombinant BSSL produced in CHO, C127 and E. coli were isolated and purified as described by Hansson et al. (1993) and Blackberg et al. (1995). 7.2 Purification of BSSL from sheep milk 24 Sheep milk samples were collected from the four sheep (cf. Section 6.1) that were found to carry the human BSSL gene, as well as from the non-transgenic sheep. The milk was centrifuged at approximately 10,000 x g for 2 h and the supernatant was poured through a sheet of Kleenex wipe to remove fat flakes/droplets on the surface. The volume of the supernatant was measured and CaCl 2 to a final concentration of 60 mM was added, the pH was adjusted to 4.3 by the addition of HCl and the samples were stirred overnight in the cold. Na 2 HPO4 was added to a concentration of 50 mM and the pH was raised to 7.4. The samples were centrifuged at 15,000 x g for 45 min and the supernatants were collected. The supernatants (whey) from one of the ewes were pooled for purification and diluted with 2 volumes of 5 mM barbiturate, 50 mM NaCl and applied to Heparin- Sepharose® and BSSL was purified as described by Blackberg and Hernell (1981). For further purification, the pooled protein from the Heparin-Sepharose® was applied to a Superdex 200 size-exclusion chromatography column. The profile obtained on Heparin-Sepharose resembled that obtained with native BSSL as well as that with recombinant full-length BSSL produced in mammalian cells. The BSSL-containing fractions were pooled and collected for a second chromatography on a Superdex 200 column. Upon this chromatography, two major peaks containing BSSL-activity were identified. When these peaks were analysed by SDS-PAGE, the peak eluting at approx. 40 min migrated as a protein of approximately the same apparent molecular mass as recombinant BSSL produced in mammalian cell culture did, while the other component eluting at approximately 50 min migrated as a considerably smaller protein (-80 kDa), probably corresponding to endogenous sheep BSSL. Both bands were fuzzy compared to the bands of the standard indicating the presence of glycosylation. 7.3 SDS-PAGE and Western blotting SUBSTITUTE SHEET 25 SDS-PAGE was performed by using precast gels in a Laemmli system. Western blotting was performed using antibodies anainst the complete protein, against amino acids 40-56, 1-535 and 712-722 as well as antibodies against the repeat part of the protein. Milk samples were analysed by western blotting using antibodies directed against native (full-length) BSSL. All positive milk samples showed a strong band at the molecular mass where C127-ρroduced BSSL could be seen, while the control milk lacks this band. It was concluded that the transgenic sheep express human BSSL protein in their milk at readily detectable levels. 7.4 Analysis of BSSL activity in sheep milk The whey was diluted 50 times with H 2 O and the activity was measured as described by Blackberg et al. (1995). From the first week of lactation, all milks were analysed each day while for the rest of the lactation period only one milk sample per week was analysed. (Fig. 4) The sample of 9 September from the sheep designated 60254 is most certainly overestimated since the volume was difficult to determine in this sample. The highest values overall were obtained with samples collected from sheep 60276. 7.5 Functional properties of BSSL The protease resistance, the pH-stability, the temperature resistance and the bile salt-stimulation was performed as described by Blackberg et al. (1995). Upon analysis of recombinant BSSL, no differences in the pH-dependence, temperature stability, the bile salt-stimulation and the protease resistance could be seen. 7.6 Monosaccharide composition After running the samples on a SDS-gel and transferring the separated proteins to a PVDF membrane, the membrane was washed in H 2 O and incubated with 26 neuraminidase in order to remove terminal sialic acids. (Sigma N-2133) at a concentration of approximately 500 U /ml in 0.1 M Tris, pH 6.5. For confirmation of O-glycosylation, the reaction with digoxygenin-labelled peanut lectin (PNA) was analysed (see Stromqvist et al., 1996). The monosaccharide composition was studied by gas chromatography and by sialic acid determination according to methods known in the art (Landberg et al., 1997). Table LV shows the monosaccharide composition of BSSL produced in transgenic sheep compared to BSSL produced in cell culture (CHO and C127 cells) and to three different samples of human native milk BSSL isolated from donated milk from three different mothers in different stages of lactation (Landberg et al., 1997). All samples of native BSSL contain fucose and the total content of monosaccharide varies from 19% to 34%. In contrast, the cell culture and sheep isolated recombinant BSSL contain no fucose but a higher content of sialic acid. It can be concluded that human BSSL from transgenic sheep appears to be very similar to the cell culture produced protein, both in total content of monosaccharides (23%) and in monosaccharide composition. DEPOSIT OF BIOLOGICAL MATERIAL The plasmid pS452 has been deposited in accordance with the Budapest Treaty at the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) on 26 February 1993 with accession number DSM 7499. REFERENCES • Ali, S. & Clark, AJ. (1988) J. Mol. Biol. 199, 415-426. • Archibald, A.L. et al. (1990) Proc. Natl. Acad. Sci. USA 87, 5178-5182. 27 Baba, T. et al. (1991) Biochemistry 30, 500-510. Blackberg, L. and Hernell, O. (1981) Eur. J. Biochem. 116, 221-225. Blackberg, L. et al. (1995) Eur. J. Biochem. 228, 817-821. Bosner, M.S. et al. (1988) Proc. Natl. Acad. Sci. U.S.A. 85(20), 7438-7442. Bradley, A. (1991) Curr. Opinion Biotechnol. 2, 823-829. Brinster, R.L. et al. (1988) Proc. Natl. Acad. Sci. U.S.A. 85, 836-840. Carver, A. et al. (1992) Cytotechnology 9, 77-84. Carver, A. et al. (1993) Bio/Technology 11, 1263-1270. Chada, K. et al. (1985) Nature 314, 377-380. Clark, AJ. et al. (1989) Bio/Technology 7, 487-492. Cooper, J.D. & Dalrymple, M.A. (1994) The Japanese Journal of Experimental Medicine, Developmental Biotechnology Supplement, 12, No.2, 124-132. Ebert, K.M. et al. (1991) Bio/Technology 9, 835-838. Evans. M.J. & Kaufman, M.H. (1981) Nature 292, 154-156. Fujiwara, Y. et al. (1997) Molec. Reprod. & Devel. 47, 157-163. Gilboa, E. et al. (1986) Biotechniques 4, 504-512. Hansson, L. et al. (1993) J. Biol. Chem. 268, 26692-26698. Harris, S. et al. (1991) Developmental Genetics 12, 299-307. Hennighausen, L. et al. (1990) Current Opinion in Biotechnology 1, 74-78. Hogan, Constantini & Lacy: "Manipulating the Mouse Embryo" (2 nd ed.) CSHP, Cold Spring Harbor, NY, USA, 1994. Hooper, M.L.: "Embryonal Stem Cells: Introducing planned changes into the animal germline", Harwood Academic, Chur, Switzerland, 1992. Jaensich, R. et al. (1975) Proc. Natl. Acad. Sci. U.S.A. 72, 4008-4012. Landberg, E. et al. (1997) Archives of Biochemistry and Biophysics 344, 94- 102. Lavitrano, M. et al. (1989) Cell 57, 717-723. Lidberg, U. et al. (1992) Genomics 13, 630-640. Loomes, K.M. & Senior, H.E.J. (1997) FEBS Letters 405, 369-372. Manson, A.L. et al. (1997) EMBO J. 16, 4238-4249. McWhir, J. et al. (1996) Nature Genetics 14, 223-226. 28 • Nilsson, J. et al. (1990) Eur. J. Biochem. 192, 443-550. • Reue, K. et al. (1991) J. Lipid Res. 32, 267-276. • Robertson, E.J. "Embryo-derived Stem Cells" in: "Teratocarcinomas and Embryonic Stem Cells, A Practical Approach", Robertson, E.J. (Ed.), pp 71- 112, LRL Press, Oxford, 1987. Schedl, A. et al. (1993) Nature 362, 258-261. Schnieke, A.E. et al. (1997) Science 278, 2130-2133. Simons, J.P. et al. (1987) Nature 328, 530-532. Simons, J.P. et al. (1988) Bio/Technology 6, 179-183. Spilburg, CA. et al. (1995) Biochemistry 34, 15532-15538. Stacey, A. et al. (1994) Mol. Cell. Biol. 14, 1009-1016. Stacey, A. et al. (1995) Proc. Natl. Acad Sci. U.S.A. 92, 2835-2839. Strδmqvist, M. et al. (1995) J. Chromatography 718(1), 53-58. Stromqvist, M. et al. (1996) Transgenic Research 5, 475-485. Umland, T. et al. "Transgenic Animals - Generation and Use", Harwood Academic Publishers, Chur, Switzerland, 1996 Velander, W.H. et al. (1992) Proc. Natl. Acad. Sci. USA 89, 12003-12007. Wang, C-S. & Johnson, K. (1983) Anal. Biochem. 133, 457-61. Wang, C-S & Hartsuck, J.A. (1993) Biochim. Biophys. Acta 1166, 1-19. Wang, C-S. et al. (1995) Biochemistry 34, 10639-10644. Whitelaw et al. (1991) Transgenic Research 1, 3-13. Wilmut, I. et al. (1997) Nature 385, 810-813. Wright, G. et al. (1991) Bio/Technology 9, 830-834. 29 TABLE I Features of plasmid pS452 Consituents Size of Sites Genetic markers fragments P UC 19 2.7 Notl ampR murine WAP, 5 -flank and 4.1 Notl / 5 -untranslated region Kpnl human BSSL 9.9 Kpnl / structural gene SaR murine WAP, 4.3 Sam structural gene Notl and 3 -flank TABLE II Summary of Sheep Study Week No. Live Lambs No. Transgenic Lambs % Transgenics/ livebirths male female Total male female Total 1 16 18 34 2 0 2 5.9 2 23 31 54 2 0 2 3.7 3 17 23 40 3 2 5 12.5 4 13 21 34 1 2 3 8.8 5 12 17 29 1 0 1 3.4 Totals 81 110 191 9 4 13 6.8 30 TABLE m Ewe-lamb Data Lamb Birth Date Age on Induction Age on First Milk 60276 1 1/4/1996 131 days 151 days 60284 13/4/1996 129 days 149 days 60254 2/4/1996 140 days 160 days 60257 5/4/1996 137 days 157 days 31 TABLE LV Monosaccharide composition The values are expressed as mass per cent of the total mass of BSSL, based on the amino acid sequence. Fuc Gal Man GalNac GlcNac Neu5Ac Total 1 - 7.5 1.5 6.3 4.2 3.1 23 2 - 5.4 0.55 3.5 1.8 8.9 20 3 - 4.2 0.64 4.2 0.84 4.3 14 4 5.5 1 1 0.36 1.7 7.8 1.8 29 5 3.5 6.5 0.22 1.2 5.2 2.0 19 6 3.7 12 0.48 1.7 12 3.2 34 7 not detectable Row Human BSSL from transgenic sheep Human BSSL produced in cultured C127 cells Human BSSL produced in cultures CHO cells Human native BSSL (individual 1) Human native BSSL (individual 2) Human native BSSL (individual 3) Human BSSL produced in transgenic mice (cf. Stromqvist et al., 1996) Abbreviations: Fuc, fucose; Gal, galactose; Man, mannose; GalNac, N-acteylgalactosamine; GlcNac, N-acetylglucosamine; Neu5Ac, 5-Ac-neuraminic acid 32 Applicant's orageπt's International apptica. file reference 1 1 -IK- 1999- H 1 754- 1 WO INDICATIONS RELATING TO DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13 bis) A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on page 5 . line 22 B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet Pj Name of depositary institution Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) Address of depositary institution /including postal code and country) Mascheroder Weg 1 b D-381 24 Braunschweig Germany Date of deposit Accession Number 26 February 1 993 DSM 7499 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet | | In respect of all designated states in which such action is possible and to the extent that it is legally permissible under the law of the designated state, it is requested that a sample of the deposited micro-organism be made available only by the issue thereof to an independent expert, in accordance with the relevant patent legislation, e.g. Rule 28(4) EPC, and generally similar provisions mutatis mutandis for any other designated state. D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for ail designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the maications e.g., "Accession Number of Deposit") For receiving Office use oπiv For International Bureau use oniv I This sheet was received with :he international aoplication D This sheet was received bv the International Bureau on: 2 1 -04- 1999 Authorized officer Authorized officer \ UΛ r f -r- ά c ^-rj Form PCT/RO/l 34 (Julv l 9981

Claims: 33 CLAIMS 1. A recombinant human bile salt-stimulated lipase produced by a transgenic non-human mammal, said lipase being glycosylated to at least 5%. 2. The recombinant human bile salt-stimulated lipase according to claim 1, wherein the transgenic non-human mammal is a placental mammal. 3. The recombinant human bile salt-stimulated lipase according to claim 1, wherein the transgenic non-human mammal is an ungulate. 4. The recombinant human bile salt-stimulated lipase according to any one of claims 1 to 3, having a total monosaccharide content of above 10%. 5. The recombinant human bile salt-stimulated lipase according to claim 4, comprising at least 1% N-acetylgalactosamine. 6. The recombinant human bile salt-stimulated lipase according to any one of claims 1 to 5, comprising the following monosaccharide composition: 0-6% fucose; 3-12% galactose; 0.1-2% mannose; 1-7% N-acetylgalactosamine; 0.5-15% N-acetylglucosamine; and 1.5-10% 5-Ac-neuraminic acid. 7. The recombinant human bile salt-stimulated lipase according to claim 6, comprising the following monosaccharide composition: 0-1% fucose; 6.5- 8.5% galactose; 1-2% mannose; 5.5-7% N-acetylgalactosamine; 3.5-5% N- acetylglucosamine; and 2.5^% 5-Ac-neuraminic acid. 8. The recombinant human bile salt-stimulated lipase according to claim 7, comprising the following monosaccharide composition: 7.5% galactose; 1.5% mannose; 6.3% N-acetylgalactosamine; 4.2% N-acetylglucosamine; and 3.1 % 5-Ac-neuraminic acid. 34 9. The recombinant bile salt-stimulated lipase according to any one of claims 1 to 8, having substantially the amino acid sequence set forth as SEQ ID NO: 3 in the Sequence Listing. 10. The recombinant bile salt-stimulated lipase according to any one of claims 1 to 8, having substantially the amino acid sequence set forth as SEQ ID NO: 4 in the Sequence Listing. 11. The recombinant bile salt-stimulated lipase according to any one of claims 1 to 8, comprising the amino acid sequence consisting functionally of SEQ ID NO: 3 in the Sequence Listing. 12. The recombinant bile salt-stimulated lipase according to any one of claims 1 to 8, comprising the amino acid sequence consisting functionally of SEQ ID NO: 4 in the Sequence Listing. 13. A transgenic sheep whose germ cells and somatic cells contain a recombinant nucleotide molecule introduced into the said sheep, or an ancestor of said sheep, at an embryonic stage, said recombinant nucleotide molecule comprising (i) a nucleotide sequence encoding for human bile salt-stimulated lipase and (ii) a promoter operatively linked to the said nucleotide sequence encoding for human bile salt-stimulated lipase. 14. A transgenic sheep according to claim 13, wherein the said nucleotide sequence encoding for bile salt-stimulated lipase is from a nucleotide sequence carried by the plasmid pS452, identified by accession number DSM 7499. 15. A transgenic sheep according to claim 13, wherein the said nucleotide sequence encoding for bile salt-stimulated lipase is from a nucleotide 35 sequence set forth as SEQ ID NO: lor SEQ ID NO: 2 in the Sequence Listing. 16. A transgenic sheep according to claim 13, wherein the said nucleotide sequence encoding for bile salt-stimulated lipase is from a nucleotide sequence encoding a polypeptide set forth as SEQ ID NO: 3 or SEQ ID NO: 4 in the Sequence Listing. 17. A transgenic sheep according to claim 13, wherein the said nucleotide sequence encoding for bile salt-stimulated lipase is from a nucleotide sequence which hybridizes with any of the sequences defined in claims 15 or 16 under stringent hybridization conditions. 18. A transgenic sheep according to claim 13, wherein the said promoter is a milk protein promoter. 19. A transgenic sheep according to claim 18, wherein the said promoter is a β- lactoglobulin promoter. 20. A female transgenic sheep according to any one of claims 13 to 19, wherein the nucleotide sequence encoding for bile salt-stimulated lipase is expressed in the mammary gland of the said female transgenic sheep, and wherein bile salt-stimulated lipase is present in the milk of the said female transgenic sheep. 21. A process for production of a female transgenic sheep according to claim 20, comprising: (a) providing a gene encoding for human bile salt-stimulated lipase operatively linked to a promoter functional in a sheep; (b) introducing said gene into an embryo or fertilized egg of a sheep, so as to incorporate said gene into the germline of the said sheep: 36 (c) transplanting said embryo or fertilized egg into a pseudopregnant host sheep; (d) allowing said host sheep to produce progeny; (e) selecting a female progeny sheep that produces recoverable amounts of bile salt-stimulated lipase in its milk. 22. A process for production of human bile salt-stimulated lipase comprising (a) producing milk in a female transgenic sheep as defined in claim 20; (b) collecting the milk produced in step (a); and, optionally, (c) isolating the bile salt-stimulated lipase. 23. A process for production of human bile salt-stimulated lipase comprising: (a) providing a gene encoding for human bile salt-stimulated lipase operatively linked to a promoter functional in a sheep; (b) introducing said gene into an embryo or fertilized egg of a sheep, so as to incorporate said gene into the germline of the said sheep: (c) transplanting said embryo or fertilized egg into a pseudopregnant host sheep; (d) allowing said host sheep to produce progeny; (e) selecting a female progeny sheep that produces recoverable amounts of bile salt-stimulated lipase in its milk; (f) collecting the milk produced by the female sheep selected in step (e); and, optionally, (g) isolating the bile salt-stimulated lipase. 24. A process according to claim 21 or 23, wherein the said gene encoding for bile salt-stimulated lipase has a nucleotide sequence selected from; (a) a nucleotide sequence carried by the plasmid pS452, identified by accession number DSM 7499; (b) a nucleotide sequence set forth as SEQ LD NO: 1 or SEQ ID NO: 2 in the Sequence Listing; 37 (c) a nucleotide sequence encoding for a polypeptide set forth as SEQ ID NO: 3 or SEQ ID NO: 4 in the Sequence Listing; (d) a nucleotide sequence which hybridizes with any of the sequences defined in (a), (b) or (c) under stringent hybridization conditions. 25. A process according to claim 21, 23 or 24, wherein the said promoter is a milk protein promoter. 26. A process according to claim 25, wherein the said promoter is a β- lactoglobulin promoter. 27. Recombinant human bile salt-stimulated lipase obtainable by the process according to any one of claims 22 to 26. 28. The recombinant human bile salt-stimulated lipase according to claim 27, said lipase being glycosylated to at least 5%. 29. The recombinant human bile salt-stimulated lipase according to claim 27, having a total monosaccharide content of above 10%. 30. The recombinant human bile salt-stimulated lipase according to claim 27, comprising at least 1 % N-acetylgalactosamine. 31. The recombinant human bile salt-stimulated lipase according to claim 27, comprising the following monosaccharide composition: 0-6% fucose; 3-12% galactose; 0.1-2% mannose; 1-7% N-acetylgalactosamine; 0.5-15% N- acetylglucosamine; and 1.5-10% 5-Ac-neuraminic acid. 32. The recombinant human bile salt-stimulated lipase according to claim 31, comprising the following monosaccharide composition: 0-1% fucose; 6.5- 8.5% galactose; 1-2% mannose; 5.5-7% N-acetylgalactosamine; 3.5-5% N- acetylglucosamine; and 2.5-4% 5-Ac-neuraminic acid. 38 33. The recombinant human bile salt-stimulated lipase according to claim 32, comprising the following monosaccharide composition: 7.5% galactose; 1.5% mannose; 6.3% N-acetylgalactosamine; 4.2% N-acetylglucosamine; and 3.1% 5-Ac-neuraminic acid. 34. The recombinant human bile salt-stimulated lipase according to any one of claims 27 to 33, having substantially the amino acid sequence set forth as SEQ ID NO: 3 or SEQ ID NO: 4 in the Sequence Listing. 5 35. A pharmaceutical preparation, comprising a bile salt-stimulated lipase according to any one of claims 1 to 12, together with one or more pharmaceutically acceptable carriers. lo 36. Use of bile salt-stimulated lipase according to any one of claims 1 to 12, in the manufacture of a medicament for the treatment of a pathological condition related to exocrine pancreatic insufficiency. 37. The use according to claim 36, wherein the exocrine pancreatic insufficiency is is a consequence of cystic fibrosis. 38. Use of bile salt-stimulated lipase according to any one of claims 1 to 12, in the manufacture of a medicament for the improvement of the utilization of dietary lipids in preterm born infants. 20 39. A method for treatment of a pathological condition related to exocrine pancreatic insufficiency which comprises administering to a mammal, including man, in need of such treatment an effective amount of bile-salt stimulated lipase according to any one of claims 1 to 12. -25 40. The method according to claim 39 wherein the exocrine pancreatic insufficiency is a consequence of cystic fibrosis. 39 41. A method for the improvement of the utilization of dietary lipids in preterm born infants which comprises administering to a preterm born infant in need of such improvement an effective amount of bile-salt stimulated lipase according to any one of claims 1 to 12.

Inventors: DALRYMPLE MICHAEL, LUNDBERG LENNART, STROEMQVIST MATS, DALRYMPLE, MICHAEL, LUNDBERG, LENNART, STROEMQVIST, MATS
Applicants: ASTRA AB, DALRYMPLE MICHAEL, LUNDBERG LENNART, PPL THERAPEUTICS, STROEMQVIST MATS, ASTRA AKTIEBOLAG, DALRYMPLE, MICHAEL, LUNDBERG, LENNART, STROEMQVIST, MATS
Application year: 1999
Main classification: C12N9
IPC codes: A01K67, A61K38, A61P1, A61P3, C12N9, C12N15